Methylation markers identify high risk patients inIGHVmutated chronic lymphocytic leukemia
| Autor: | Anton Parker, Gordon Strathdee, Rachel E. Ibbotson, Laura Irving, David Oscier, Tryfonia Mainou-Fowler |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Genes Immunoglobulin Heavy Chain Chronic lymphocytic leukemia Cell Cycle Proteins Biology CD38 medicine.disease_cause Cohort Studies Risk Factors immune system diseases hemic and lymphatic diseases Internal medicine Biomarkers Tumor medicine Humans Molecular Biology Gene Proportional Hazards Models Homeodomain Proteins Mutation Membrane Glycoproteins Proportional hazards model Brief Report Methylation DNA Methylation medicine.disease ADP-ribosyl Cyclase 1 Leukemia Lymphocytic Chronic B-Cell DNA methylation Immunology Female IGHV@ Transcription Factors |
| Zdroj: | Epigenetics. 6:300-306 |
| ISSN: | 1559-2308 1559-2294 |
| Popis: | Chronic lymphocytic leukemia (CLL) exhibits a highly variable clinical course. Altered DNA methylation of genes has shown promise as a source of novel prognostic makers in a number of cancers. Here we have studied the potential utility of a panel of methylation markers (CD38, HOXA4 and BTG4) in 118 CLL patients. Each of the three loci assessed exhibited frequent methylation, as determined by COBRA analysis and individually correlated with either good (CD38, BTG4 methylation) or poor (HOXA4 methylation) prognosis. Using a combined approach to produce an overall methylation score, we found that methylation score was significantly associated with time to first treatment in CLL patients. Multivariate Cox regression analysis revealed that methylation score was the strongest predictor of time to first treatment and was independent of IGHV gene mutational status and CD38 expression. This study provides proof of principle that a panel of methylation markers can be used for additional risk stratification of CLL patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|